Modern day cardiology care is a multidisciplinary subspecialty, encompassing the heart’s pump function, its blood supply via the coronary arteries, valvular integrity, and the electrical system. The field of cardiology is constantly evolving and is a true collaborative endeavor. Cardiac electrophysiology (EP) is the discipline dedicated to identifying and treating disorders of the electrical conduction system of the heart.
Over the past decade, the field of electrophysiology has made considerable breakthroughs and it continues to innovate to reduce patient morbidity and mortality. Electrophysiology is critical to comprehensive cardiovascular care, with interventions that improve heart failure outcomes, quality of life, cardiovascular mortality, hospitalizations, and reduce stroke risk.
Interventional EP can be viewed in three major domains: (1) arrhythmia management via catheter based ablation (2) implantation of cardiac implantable electronic devices (CIED), which include pacemakers and defibrillators and (3) transcatheter left atrial appendage occlusion for stroke risk reduction. All three areas are undergoing major advancements and breakthroughs through research and innovation.
Catheter ablation offers durable, often curative, treatment for many arrhythmias including supraventricular tachycardia, ventricular tachycardia, and atrial fibrillation. While the etiology and targets for these various arrhythmias differ based on the clinical situation, the approach is consistent: catheters are inserted via the peripheral venous and/or arterial system (most commonly via the femoral vein) and energy is applied to targeted locations to terminate or modulate arrhythmia.
While catheter ablation of cardiac arrhythmia is one of the most performed cardiac procedures today, it is still a relatively young field. Programmed electrical stimulation of the intact heart via intracardiac catheters was first described in 1967. Intervention was initially surgical; guidance was provided via the knowledge learned from these intracardiac studies and treatment was performed by cardiac surgeons. In 1981, Dr Melvin Scheinmann performed the first catheter-based ablation via direct current defibrillator discharges to the AV node in a patient with atrial fibrillation.1 In 1988 Dr Jonathan Langberg published the first series on cardiac catheter ablation of the AV node via radiofrequency energy, catalyzing successive advances in ablation techniques. Subsequent decades introduced additional modalities of ablation including cryotherapy ablation in the 1990s, and more recently pulsed field ablation, a non-thermal therapy that delivers short bursts of high energy.
Catheter ablation of atrial fibrillation was first reported by Dr JF Swartz in 19943 and expanded by Dr Michel Haissaguere in 1996. Early treatment sets mimicked the surgical MAZE procedure before evolving to focus on demonstrated triggers, primarily in the pulmonary veins, first described by Dr Haissaguerre in 1998. Refinement of these initial techniques have made ablation of atrial fibrillation one of the most frequently performed catheter-based intervention for cardiac arrhythmias, comprising 25% of all ablation procedures in 2020. This growth is timely, given the ever-rising global incidence and prevalence of AF, and its known correlation with heart failure, valve disease, stroke, impaired quality of life, and high cost of care.
The field of cardiac pacing and implantable defibrillation has likewise advanced rapidly. By the 18th century, it was established that electricity is intrinsic to human function. In a rather morbid extension of the growing knowledge of human physiology and the physics of electricity, it was established that hearts from decapitated humans could be made to beat with application of electric currents. The 19th century saw further experimentation on the relationship between electricity and the mechanical contraction of the heart, and the first electrocardiogram was recorded by Willem Einthoven in 1892.
The first external pacemakers used needles directly inserted into the heart tissue and used either alternative current or direct current to stimulate the heart. Created by Mark Lidwell in 1928 and Albert Hyman in 1932, these were rudimentary systems, and it took many decades for a usable pacemaker to be developed. In 1952 Paul Zoll designed an external transcutaneous pacemaker. In 1958, Earl Bakken and C. Walton Lillehei together developed the first battery operated wearable pacemaker with energy delivered via a myocardial wire, and this same year saw the first fully implantable pacemaker engineered by Rune Elmqvist and implanted by Dr Ake Senning.
The implantable cardioverter defibrillator (ICD) for prevention of sudden cardiac death was first invented by Dr Michel Mirowski in the 1970s. The first ICD was implanted in a human in 1980, with an epicardial defibrillation patch requiring a thoracotomy, and the generator weighed 225 grams. Many iterations have followed, with the first advances moving from an epicardial patch to a transvenous lead with both pacing and defibrillating capabilities, and a generator that has reduced in weight to about 80 grams.8 The adoption of the ICD for both primary and secondary prevention of sudden cardiac death has been transformative.
Over the subsequent decades, major advancements in cardiac pacing and defibrillation have been achieved with experimentation driven directly by patient needs. Pacing that mimics normal physiology is a constant goal, first tackled with developments like rate response and cardiac resynchronization therapy, and in more recent years with conduction system pacing in both the atrium via Bachmann bundle pacing and the ventricles with His bundle and left bundle pacing. While significant improvements in lead and pulse generator design over the years have allowed for more reliable lead performance and smaller pulse generators, complications of infection and vascular complications persist. This has led to the development of leadless pacemakers, delivered via catheter directly into the heart, and extravascular devices, primarily defibrillators.
In this issue of Atlanta Medicine are a collection of articles from experienced and leading electrophysiology professionals from across the metro Atlanta area. Together, they cover both the foundations of EP care and the field’s most important breakthroughs. In the spirit of past trailblazers and in response to evolving patient needs, electrophysiology will continue to advance rapidly, improving outcomes for patients with cardiac arrhythmias.
References:
1. Kuijpers, Petra. e-Journal of Cardiology Practice. ESC. History in medicine: the road to clinical electrophysiology. 21(13) 15 Dec 2021.
2. Langberg, Jonathan et al. Circulation Vol 80, No 6, December 1989. 1527-1535. 1987
3. Swartz, JF et al. A catheter based curative approach to atrial fibrillation in humans. Circulation 1994; 90(Suppl I):I–335 (abstract).
4. Haissaguerra, Michel at al. Ablation of paroxysmal atrial fibrillation. Journal of Cardiovascular Electrophysiology. 7(12). December 1996. 1132-1144.
5. Haissaguerra, Michel at al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. NEJM 339 (10). September 1998. 659-666
6. Scott, Monte et al. Contemporary trends in cardiac electrophysiology procedures in the United States, and impact of a global pandemic. Heart Rhythm O2 , Vol 4, No 3, March 2023. 193-199.
7. Aquilina O. A brief history of cardiac pacing. Images in Paediatric Cardiology. 2006. April-June 8(2): 17-81
8. Deyell, Marc. The implantable cardioverter-defibrillator: From Mirowski to its current use. BCMJ. 52(5) June 2010. 248
Stacy Westerman, MD, MPH
Dr. Westerman completed her undergraduate degree at Columbia University in New York, followed by her medical and public health degrees at Emory University. After completing internal medicine residency in Seattle, Washington, she returned to Atlanta for her fellowships in cardiovascular disease and cardiac electrophysiology. Her particular interests include cardiac implantable devices, complex ablations, and women’s health. Dr. Westerman is part of the Arrhythmia Center, which offer advanced treatment for atrial fibrillation (A-fib) and heart arrhythmias.


